文献速递浆细胞疾病

不适合移植多发性骨髓瘤真实世界治疗结局:加拿大骨髓瘤研究组数据库多中心报告

Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
PubMed 文献 · Br J Haematol · 2021-02-09

基于加拿大骨髓瘤研究组数据库评估1156例不适合移植多发性骨髓瘤(TIMM)患者,82%接受含硼替佐米方案、18%接受来那度胺联合低剂量地塞米松(Ld)。两种含硼替佐米三药方案间无显著差异,VD/P双药方案结局较差,Ld无进展生存期更长但总生存期未显著优于含硼替佐米方案。

要点

  • VMP与CyBorD/P三药方案的真实世界PFS和OS无显著差异。
  • VD/P双药方案PFS与OS均劣于三药方案及Ld。
  • Ld的PFS优于含硼替佐米方案,但OS未显示显著优势。

核心结论

  • 在TIMM真实世界中,Ld的PFS长于含硼替佐米方案,但OS未显著优于含硼替佐米方案。
  • VMP与CyBorD/P两种三药方案间PFS和OS无显著差异,VD/P双药方案结局较差。
  • 多变量分析显示疾病生物学特征是与PFS和OS相关的最重要预后因素。

研究设计与样本

  • 多中心回顾性队列研究,数据来自加拿大骨髓瘤研究组数据库。
  • 共纳入1156例不适合移植多发性骨髓瘤患者,82%接受含硼替佐米方案,18%接受Ld。

主要发现

  • VMP与CyBorD/P之间PFS和OS无显著差异。
  • Ld较含硼替佐米方案PFS更长,但OS至今未显著更优。
  • VD/P双药方案结局劣于其他方案。

临床怎么用

  • 真实世界结果与临床试验报告相似,支持含硼替佐米三药方案与Ld均可作为TIMM的一线选择。
  • 方案选择需结合疾病生物学特征及影响医师选择方案的因素综合判断。

局限性

  • 为回顾性数据库研究,方案选择非随机,医师选择方案的因素可能影响组间比较。
  • 疾病生物学特征等预后因素在不同方案组间的分布可能影响观察到的结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bortezomib-containing regimens (BCRs) represented standard, first-line therapy for transplant-ineligible multiple myeloma (TIMM) in Canada until the introduction of lenalidomide and low-dose dexamethasone (Ld). However, little comparative data exist to inform the selection of regimens. We assessed the outcomes for TIMM patients treated with cyclophosphamide, bortezomib and dexamethasone or prednisone (CyBorD/P), bortezomib, melphalan and prednisone (VMP), bortezomib and dexamethasone or prednisone (VD/P) and lenalidomide and low-dose dexamethasone (Ld) using the Canadian Myeloma Research Group database. Of 1156 TIMM patients evaluated, 82% received bortezomib combinations while 18% received Ld. Median progression-free survival (PFS) was 21·0, 21·1, 13·2 and 28·5 months (P = 0·0002) and median overall survival (OS) was 52·0, 63·6, 30·8 and 65·7 months (P < 0·0001) in the CyBorD/P, VMP, VD/P and Ld groups respectively. There was no significant difference in PFS and OS between the two triplet bortezomib regimens (VMP and CyBorD/P). Ld was associated with a longer PFS but not a significantly superior OS to date. Outcomes with the bortezomib-steroid doublet were inferior (VD/P). However, multivariable analysis identified features related to disease biology as the most important prognostic factors for PFS and OS. Such factors, as well as those affecting the physician's choice of regimen, are likely to influence the results observed with different regimens. This study demonstrated real-world outcomes in TIMM similar to those reported in clinical trials.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jimenez-Zepeda VH, Venner C, McCurdy A, et al. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database. Br J Haematol. 2021. PMID: 33559897. doi:10.1111/bjh.17350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。